Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 61

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 61
---
.68 | % |
| Wendy Chung (8)                                              |     |                        |     58,576 |     |                      |       | * |
| Kaye Foster (8)                                              |     |                        |     58,576 |     |                      |       | * |
| Michael Kelly (8)                                            |     |                        |     58,576 |     |                      |       | * |
| Jeffrey Marrazzo (8)                                         |     |                        |    311,333 |     |                      |       | * |
| Robert Nelsen (2) (11)                                       |     |                        | 15,511,736 |     |                      | 11.83 | % |
| David Schenkein (8)                                          |     |                        |     39,062 |     |                      |       | * |
| All executive officers and directors as a group (13 persons) |     |                        | 30,079,030 |     |                      | 22.93 | % |

* Less than one percent.

(1) Consists of: (a) 20,156,945 shares of common stock, and (b) 93,515 shares of common stock underlying options exercisable within 60 days of March 31, 2025.

(2) Information herein is based on Schedule 13D/A filed with the SEC on November 22, 2024 by (1) ARCH Venture Fund X, L.P. (“AVF X”), (2) ARCH Venture Partners X, L.P. (“AVP X LP”), which is the sole general partner of AVF X, (3) ARCH Venture Partners X, LLC (“AVP X LLC”), which is the sole general partner of AVP X LP and AVP X Overage LP (defined below), (4) ARCH Venture Fund X Overage, L.P. (“AVF X

<div align='center'>40</div>

Overage”), (5) ARCH Venture Partners X Overage, L.P. (“AVP X Overage LP”), which is the sole general partner of AVF X Overage, (6) ARCH Venture Fund XII, L.P. (“AVF XII”), (7) ARCH Venture Partners XII, L.P. (“AVP XII LP”) which is the sole general partner of AVF XII, (8) ARCH Venture Partners XII, LLC (“AVP XII LLC”) which is the sole general partner of AVP XII LP, (9)